Observational studyCirculation. Heart failure2022
Cardiogenic Shock From Heart Failure Versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and 1-Year Outcomes.
2 registry-linked trialsOpen access · greenAbstract readObservational Study
In one paragraph
Observational study in Circulation. Heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
7.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Implementation of a Cardiogenic Shock Team and Clinical Outcomes (INOVA-SHOCK Registry)
The Role of Swan-Ganz Catheter in Hemodynamic Resuscitation for Patients With Cardiogenic Shock
Who cites it
50 citing papers in PubMed, 104 citations in OpenAlex.
- Comparative Outcomes of Direct Impella Use vs. Intra-Aortic Balloon Pump (IABP)-to- Impella Escalation Strategy in Cardiogenic Shock: Insights from the National Inpatient Sample.Research square · 2026Article
- Palliative and End-of-Life Care Utilization in Cardiogenic Shock Complicating Acute Myocardial Infarction: A Population-Based Study.JACC. Advances · 2026Article
- Characteristics, Management, and Outcomes of Diabetes Subtypes in Patients With Cardiogenic Shock: A Nationwide Analysis.JACC. Advances · 2026Article
- The Challenge of Cardiogenic Shock Transfers: The Devil in the Details.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Clinical Profiles and Prognostic Patterns in Critically Ill Cardiac Patients Requiring Invasive Mechanical Ventilation: A Five-Year Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Cardiogenic Shock Systems of Care Best Practices. Part 1: Prehospital and Emergency Department Evaluation and Management.US cardiology · 2026Review
- Factors associated with native heart survival and intermediate-term outcomes in acute myocardial infarction-related cardiogenic shock.European heart journal open · 2026Article
- Cardiogenic Shock Systems of Care Best Practices, Part 3: Regionalization of Care, Organizational Components, and Critical Care Transport Medicine.US cardiology · 2026Review
- Cardiogenic shock in cancer: differences in use of temporary mechanical circulatory support, invasive hemodynamic assessment and patient outcomes.Cardio-oncology (London, England) · 2025Article
- Cardiogenic Shock Management in the Modern Era: A Narrative Review of Percutaneous Mechanical Circulatory Support Devices.Journal of cardiovascular development and disease · 2025Review
- Safety and Prognostic Implications of Mechanical Circulatory Support-Assisted Transcatheter Edge-to-Edge Repair: The OCEAN-Mitral Registry.Journal of the American Heart Association · 2025Observational
- A Proposed Algorithm for the Management of Patients with Cardiogenic Shock Based on Contemporary Knowledge and Gaps in Evidence.Journal of cardiovascular development and disease · 2025Review
- A Contemporary Guide of Venoarterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock.Journal of cardiovascular development and disease · 2025Review
- Impact of standardized team-based care on cardiogenic shock outcomes over time.ESC heart failure · 2025Article
- Special topics: heart failure-related cardiogenic shock, valvular heart disease and end-stage renal disease. Part 4 of the International Expert Opinion Series on Acute Heart Failure Management.Heart failure reviews · 2025Review
- Cardiogenic shock: a review of contemporary approaches and ongoing challenges.Future cardiology · 2025Review
- Timing of inotropic support is associated with mortality in patients with acute decompensated heart failure-associated cardiogenic shock.Intensive care medicine experimental · 2025Article
- Management Patterns and Outcomes of Invasive Mechanical Ventilation in Patients With Cardiogenic Shock.JACC. Advances · 2025Article
- Impact of Baseline Cardiogenic Shock Severity on Outcomes in Patients Treated With Impella Device.Journal of the American Heart Association · 2025Observational
- Treatment of heart failure related cardiogenic shock: Time to fill the evidence gap.ESC heart failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 4 institutions in 2 countries.
Shashank S Sinha *Inova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).
Carolyn M Rosner *Inova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).ORCID 0000-0002-7742-9628
Behnam N TehraniInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).
Aneel MainiGeorgetown University Medical School' Washington' DC (A.M.).
Alexander G TruesdellInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).ORCID 0000-0001-5656-4401
Seiyon Ben LeeDepartment of Statistics, George Mason University' Fairfax' VA (S.B.L., P.B., J.C.).
Pramita BagchiDepartment of Statistics, George Mason University' Fairfax' VA (S.B.L., P.B., J.C.).
James CameronDepartment of Statistics, George Mason University' Fairfax' VA (S.B.L., P.B., J.C.).
Abdulla A DamlujiInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).ORCID 0000-0002-8774-6416
Mehul DesaiInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).
Shashank S DesaiInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).ORCID 0000-0001-9757-9650
Kelly C EppsInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).
Christopher deFilippiInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).ORCID 0000-0002-0660-4943
M Casey FlanaganInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).ORCID 0000-0003-4460-0975
Leonard GenoveseInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).ORCID 0000-0002-0950-9861
Hala MoukhachenInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).
James J ParkInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).
Mitchell A PsotkaInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).
Anika RajaInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).
Palak ShahInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).ORCID 0000-0001-8175-168X
Matthew W SherwoodInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).ORCID 0000-0002-4305-5883
Ramesh SinghInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).ORCID 0000-0003-3505-3930
Daniel TangInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).
Karl D YoungInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).ORCID 0000-0001-9126-5810
Timothy WelchInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).
Christopher M O'ConnorInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).
Wayne B BatchelorInova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA (S.S.S., C.M.R., B.N.T., A.G.T., A.A.D., M.D., S.S.D., K.C.E., C.d., M.C.F., L.G., H.M., J.J.P., M.A.P., A.R., P.S., M.W.S., R.S., D.T., K.D.Y., T.W., C.M.O., W.B.B.).ORCID 0000-0002-3016-1150
Norwegian Womens Public Health Association · NOGeorge Mason University · USTechnical Data Analysis (United States) · USGeorgetown University · US
Funding
Technological Assessment and Solutions Core - RC4P30AG021334 · NIA · JOHNS HOPKINS UNIVERSITY · PI Jeremy D Walston · 2003 to 2026
$33.2MThe integrated Translational Health Research Institute of Virginia (iTHRIV): Using Data to Improve HealthUL1TR003015 · NCATS · UNIVERSITY OF VIRGINIA · PI BROWN, DONALD E, JOHNSTON, KAREN C. · 2019 to 2023
$20.3MAvoiding (Heart) Failure: Physiologic-Based Targeting of the RAAS to Treat Subclinical HFpEF among PWHR01HL151293 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI SRINIVASA, SUMAN · 2020 to 2024
$4.2MThe optimal loop diuretic: mechanistic insights from longitudinal changes in blood and urine proteins to explain efficacy and safety of torsemide vs furosemide after a heart failure hospitalizationR01HL154768 · NHLBI · INOVA HEALTH CARE SERVICES · PI COOPER, LAUREN BETH, DEFILIPPI, CHRISTOPHER R · 2020 to 2023
$1.6MMicroRNA Biomarkers of Allograft Rejection and Cardiac Allograft Vasculopathy in Cardiac TransplantationK23HL143179 · NHLBI · INOVA HEALTH CARE SERVICES · PI SHAH, PALAK · 2020 to 2024
$927kFrailty and Resiliency in Older Adults with Acute Myocardial InfarctionK23HL153771 · NHLBI · INOVA HEALTH CARE SERVICES · PI DAMLUJI, ABDULLA AL · 2020 to 2024
$916kClonal hematopoiesis and severity of COVID-19 diseaseR21AG072095 · NIA · UNIVERSITY OF VIRGINIA · PI DEFILIPPI, CHRISTOPHER R, WALSH, KENNETH · 2021 to 2022
$457kNCATS NIH HHS UL1 TR003015NHLBI NIH HHS K23 HL143179NHLBI NIH HHS K23 HL153771NHLBI NIH HHS L30 HL134124NHLBI NIH HHS R01 HL151293NHLBI NIH HHS R01 HL154768NIA NIH HHS P30 AG021334NIA NIH HHS R21 AG072095
Abstract
backgroundLittle is known about clinical characteristics, hospital course, and longitudinal outcomes of patients with cardiogenic shock (CS) related to heart failure (HF-CS) compared to acute myocardial infarction (AMI; CS related to AMI [AMI-CS]).
methodsWe examined in-hospital and 1-year outcomes of 520 (219 AMI-CS, 301 HF-CS) consecutive patients with CS (January 3, 2017-December 31, 2019) in a single-center registry.
resultsMean age was 61.5±13.5 years, 71% were male, 22% were Black patients, and 63% had chronic kidney disease. The HF-CS cohort was younger (58.5 versus 65.6 years,
conclusionsPatients with HF-CS were younger, and despite lower cardiac power output and higher pulmonary capillary wedge pressure, less likely to receive vasopressors or temporary mechanical circulatory support. Although patients with HF-CS had lower in-hospital and 1-year mortality, both cohorts experienced similarly high rates of postdischarge major adverse cardiovascular and cerebrovascular events and 30-day readmission, highlighting that both cohorts warrant careful long-term follow-up. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03378739.
Indexed as
Heart FailureMyocardial InfarctionAftercareAgedFemaleHospital MortalityHospitalsHumansMaleMiddle AgedPatient DischargeShock, Cardiogenicheart failurehemodynamicsmortalitymyocardial infarctionshock, cardiogenic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03378739ClinicalTrials.gov
NCT07062744ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.